Form 4: Bioventus Inc. CEO Robert E. Claypoole Reports Stock Transaction
SEC Form 4 Filing
Robert E. Claypoole, President and CEO of Bioventus Inc., reports the vesting and conversion of restricted stock units into Class A Common Stock on January 10, 2025.
Summary
- On January 10, 2025, Robert E. Claypoole, the President and CEO of Bioventus Inc., executed a transaction involving restricted stock units.
- 93,750 restricted stock units vested and were converted into 93,750 shares of Class A Common Stock.
- Following the transaction, Claypoole directly owns 93,750 shares of Class A Common Stock and 281,250 restricted stock units.
- The restricted stock units vest in four equal installments on each of the first four anniversaries of January 10, 2024, contingent upon continued service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and is a common occurrence for publicly traded companies like Bioventus Inc.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 01/10/2024 | Initial vesting date for restricted stock units, with subsequent vesting occurring annually for four years. |
| 01/10/2025 | Date of transaction: vesting and conversion of 93,750 restricted stock units into Class A Common Stock. |
| 01/13/2025 | Date of report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.